Agree with you Barsax, last July McCaffrey got about 1.4 million RSU's and now he's taking another 400+ thousand and what have shareholders got besides more hot air. RSU's are just regular shares and taxed as income when vested and exercised. In my opinion, with an underperforming company if the BoD really wanted to incentivize management they would at the very most issue options with an expiration date and (as is common practice) a strike price at the current share price.

Again my opinion but to me the BoD have completely failed in their fiduciary duty to all shareholders but I don't think it will change. Management says the company has a $4B EV (after BoM reveal but pre CoVid opportunity) out of which they can only squeeze a $200M market cap. 5 cents on the dollar MC/EV is pathetic yet these guys are paid like they are high performing biotech management. Large investors however, who likely have a much better view than us regular folks, get to invest at 5 cents on the dollar plus warrants so they are probably happy.  Pretty sad. I imagine the real reason we don't get to see the Deloitte report is that even discounted it shows a much higher value than current market cap which again is a poor reflection on management performance (Don said the report put a much higher value on shares than current sp). Again, sad. 

I think the senior science team is well paid, and deserve every bit of it.